• Explore /
  • Poster
  • / Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).

Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).

Abstract Video & Slides Poster

Authors

null

Sant P. Chawla

Sarcoma Oncology Research Center, Santa Monica, CA

Sant P. Chawla , Victoria S. Chua-Alcala , Jasgit C. Sachdev , David S. Wages , David D. Stenehjem , Daniela Y. Santiesteban , Nadeem Q. Mirza , Michael S. Gordon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT03895684

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3073)

DOI

10.1200/JCO.2021.39.15_suppl.3073

Abstract #

3073

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Philippe L. Bedard

First Author: Filippo G. De Braud

First Author: Judy S. Wang

First Author: John D. Powderly